H
HeyPsych
PsychTrails™TreatmentsConditionsResourcesFor CliniciansAbout

Stay updated on mental health treatments

Get the latest research, treatment updates, and evidence-based insights delivered to your inbox. No spam, just valuable mental health information.

Coming Soon

Newsletter subscription will be available soon.

H
HeyPsych

Evidence-based mental health treatment education platform. Helping you make informed decisions about your mental health journey.

Treatments

  • Medications
  • Interventional
  • Investigational
  • Alternative
  • Therapy
  • Supplements

Conditions

  • Depression
  • Anxiety
  • ADHD
  • Bipolar
  • All Conditions

Resources

  • Assessments & Screeners
  • Support & Community
  • Digital Tools
  • Knowledge Hub
  • PsychTrails™

Company

  • About Us
  • Privacy Policy
  • Terms of Service
  • Contact

© 2026 HeyPsych (PsychTrails™). All rights reserved.

Made with for better mental health
v2.2.0

Atomoxetine (Strattera)

FDA Approved 2002

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Published December 1, 2025•Updated December 1, 2025•Reviewed December 1, 2025

Clinical summary for Atomoxetine (Strattera): Atomoxetine (brand name Strattera, plus multiple generics) is a non-stimulant medicine for ADHD in kids, teens, and adults. It works differently from stimulants like methylphenidate or amphetamine and has no known abuse or addiction potential. It is usually used when stimulants cause too many side effects, don’t work well enough, or are not a good fit (for example, in people with tics or a history of substance misuse).

You take atomoxetine as a capsule once or twice a day. It does not work instantly—symptoms often improve gradually over a few weeks. Common side effects include upset stomach, decreased appetite, nausea, dry mouth, trouble sleeping, and feeling tired or dizzy. It can raise blood pressure and heart rate a little, so vitals need to be checked regularly.

There are some important warnings: atomoxetine can increase suicidal thoughts in a small number of children and teens, especially in the first month of treatment, so close monitoring by family and clinicians is essential. Rarely, it can seriously injure the liver (yellow eyes/skin, dark urine, severe fatigue) or cause significant heart problems in people with underlying heart disease. Any major mood changes, suicidal thoughts, chest pain, fainting, or signs of liver trouble should be reported immediately. Atomoxetine is not approved to treat depression.

What It’s Used For

Atomoxetine is a non-stimulant medication for ADHD, with some niche off-label uses.

Primary Indications

Attention-Deficit/Hyperactivity Disorder (ADHD) in children ≥6 years, adolescents, and adults: Inattention, hyperactivity, and impulsivity across home, school, and work settings.Patients who cannot tolerate stimulants (eg, significant side effects, appetite/weight issues, mood or sleep problems).Patients with a history of substance misuse or diversion where stimulants may be higher risk.Patients with tics or Tourette syndrome, where atomoxetine may be better tolerated than stimulants.

Off-Label Uses

Neurogenic orthostatic hypotension with normal or elevated norepinephrine levels (symptom management when nonpharmacologic measures are inadequate).Adjunctive use in ADHD with comorbid anxiety disorders when stimulants worsen anxiety (requires close monitoring).

What People Commonly Notice

Experiences vary, but these are typical themes reported by patients and families:

Onset and Symptom Change

"It didn’t feel like anything at first, then over a few weeks I could focus longer."

How Fast It Works

Atomoxetine builds up gradually, so expectations should be different from stimulants.

First week

GI side effects (nausea, stomach upset, decreased appetite) and mild sleep changes are often more noticeable than ADHD benefit.

2–4 weeks

Many patients begin to notice improved attention, organization, and impulse control.

4–8 weeks

Full therapeutic effect is usually assessed; dose adjustments may be made based on response and tolerability.

Once- or twice-daily dosing

Duration of action can cover the full day with appropriate dosing; there is no sharp ‘wear-off’ like some short-acting stimulants.

How Well It Works

ADHD Symptom Reduction

Moderate effect size vs placebo
vs Typically less potent and slower onset than stimulants but clinically meaningful for many patients.
Across multiple randomized controlled trials, atomoxetine improves core ADHD symptoms (inattention, hyperactivity, impulsivity) compared with placebo in children, adolescents, and adults. The onset is gradual and the average effect is somewhat smaller than with stimulant medications, but atomoxetine still provides meaningful benefit for many patients, especially when stimulants are not an option.

Critical Safety Information

Critical Safety Information

Suicidal ideation warning in children and adolescents; rare severe liver injury; cardiovascular and growth effects; not approved for major depressive disorder.
  • →For children and teens: families must watch closely for new or worsening depression, irritability, agitation, or suicidal thoughts—especially in the first month and after dose changes. Report any concern immediately.
  • →Seek urgent care immediately for symptoms of liver injury (yellow eyes/skin, dark urine, severe fatigue, upper abdominal pain).
  • →Report chest pain, fainting, racing or irregular heartbeat, or unexplained shortness of breath right away.
  • →If you have a painful erection or an erection lasting more than 4 hours (even without sexual activity), go to the emergency department immediately.
  • →Do not stop or change the dose abruptly without talking to your prescriber, especially if symptoms are well controlled.
  • →This medication is for ADHD, not for depression. It should not be used as an antidepressant.

Side Effects

Common side effects involve the GI tract, appetite, sleep, cardiovascular system, and mood/energy. Most are dose-related and often improve over time, but serious events can occur.

Common Things People Notice

  • Stomach issues: nausea, stomach pain, decreased appetite, vomiting, constipation.
  • Headache, trouble sleeping, feeling tired or sleepy.
  • Dry mouth, dizziness, sweating.
  • Increased heart rate or blood pressure.
  • Mood changes: irritability, emotional ups and downs, occasional depressed mood.
  • Sexual side effects in adults (e.g., erectile or ejaculatory problems).

Common Side Effects

Nausea 7%–26%; abdominal pain 7%–18%; decreased appetite 15%–23%; vomiting 4%–11%; constipation 1%–11%
Gastrointestinal upset (nausea, abdominal pain, decreased appetite, vomiting, constipation)— GI side effects are most prominent in the first 1–3 months and often improve. Taking with food (if tolerated) and slow titration can help.
17%–35%
Dry mouth (xerostomia)— Common in adults. Sugar-free gum, sips of water, and good dental care may help.
Up to ~19%
Insomnia and sleep disturbance— Trouble falling or staying asleep can occur, especially if doses are taken too late in the day. Morning dosing or splitting the dose can sometimes help.
Drowsiness 8%–11%; fatigue 6%–10%
Drowsiness, fatigue, or tiredness— Some people feel more tired instead of more alert. Adjusting dose timing (e.g., more in the evening) can sometimes reduce daytime fatigue.
Clinically significant increases (eg, HR ≥20 bpm, BP ≥15–20 mm Hg) in ~8%–12%
Blood pressure and heart rate increases— Most increases are modest but should be monitored. Tell your clinician if you develop persistent headaches, chest pain, or palpitations.
Erectile dysfunction 8%–21%; ejaculatory disorder 2%–6%; decreased libido ~3%
Sexual dysfunction (mainly adults)— These side effects are often dose-related and may improve over time or with dose adjustment.

⚠️ Serious Side Effects

  • Suicidal ideation or behavior (especially in children and adolescents).
  • Severe liver injury, including acute liver failure (rare; may require transplant).
  • Serious cardiovascular events: sudden cardiac death, myocardial infarction, stroke (rare; mainly in high-risk patients).
  • Clinically significant QTc prolongation and torsades de pointes (very rare; higher risk with overdose, poor metabolizers, or coadministered QT-prolonging drugs).
  • Psychosis, mania, or hypomania (hallucinations, markedly elevated or irritable mood, decreased need for sleep).
  • Severe aggression, hostility, or activation syndrome (aggravation of ADHD symptoms plus irritability, disinhibition, insomnia).
  • Priapism (painful or prolonged erections).
  • Rhabdomyolysis (rare muscle breakdown).

Important Drug Interactions

Atomoxetine is metabolized mainly by CYP2D6 and can interact with many cardiovascular and psychotropic medications.

With: Monoamine oxidase inhibitors (MAOIs) and recent MAOI use (within 14 days)

Risk: Serious, potentially life-threatening reactions (e.g., hypertensive crisis, neurotoxicity).

Action: CONTRAINDICATED. Do not use atomoxetine with MAOIs or within 14 days of stopping an MAOI.

With: Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine, bupropion)

Risk: Marked increase in atomoxetine levels (AUC up to ~10-fold in poor metabolizers), raising risk of side effects (BP/HR changes, liver injury, psychiatric effects).

Action: Start atomoxetine at reduced doses (≤0.5 mg/kg/day in children ≤70 kg; 40 mg/day in adults or ≥70 kg) and only increase after ≥4 weeks if needed and tolerated.

With: Moderate CYP2D6 inhibitors or CYP2D6 substrates

Risk: Increased atomoxetine or co-medication levels; potential toxicity.

Action: Monitor closely and adjust doses as needed.

With: Other QT-prolonging drugs (e.g., some antipsychotics, macrolide antibiotics, class Ia/III antiarrhythmics, methadone)

Risk: Additive QTc prolongation and arrhythmia risk.

Action: Avoid if possible; if necessary, monitor ECG and electrolytes, and minimize other risk factors.

With: Sympathomimetics and beta-2 agonists (e.g., albuterol, decongestants, stimulants)

Risk: Additive increases in heart rate and blood pressure.

Action: Monitor BP and HR more frequently; use the lowest effective doses; consider alternatives for decongestion (e.g., saline sprays).

With: Iobenguane radiopharmaceutical products

Risk: Atomoxetine may decrease uptake and therapeutic effect.

Action: Stop atomoxetine (and similar drugs) for at least 5 half-lives before iobenguane and avoid restarting for at least 7 days after each dose.

With: Other psychotropics associated with priapism (e.g., trazodone) or urinary retention

Risk: Increased risk of priapism and urinary retention.

Action: Use caution; educate about priapism warning symptoms and urinary difficulties.

Stopping or Changing Atomoxetine Safely

Atomoxetine is not known to cause classic physical dependence, but abrupt changes can lead to symptom rebound and mood destabilization.

Key Points

  • In most cases, atomoxetine can be tapered over 1–2 weeks when stopping, especially after long-term use, to monitor for return of ADHD symptoms and mood changes.
  • Rapid discontinuation may be necessary if severe side effects occur (e.g., liver injury, severe cardiovascular or psychiatric reactions), but this should be done under medical supervision.
  • When switching from a stimulant to atomoxetine, some clinicians overlap briefly while others cross-taper. Conversely, when switching from atomoxetine to a stimulant, atomoxetine is often tapered while the stimulant is introduced.
  • Monitor for worsening ADHD symptoms, emergent depression or anxiety, irritability, or suicidal thoughts during dose reductions.
  • Families and caregivers should be involved in monitoring children and adolescents for behavioral changes throughout the taper.

Dosing Information

Adult Dosing

adhd initial: 40 mg orally once daily.

adhd titration: After ≥3 days, increase to ~80 mg/day (given once daily in the morning or divided into morning and late afternoon/early evening).

adhd max: 100 mg/day (in 1 or 2 divided doses); doses above 100 mg/day are not recommended.

adhd poor metabolizer: Known CYP2D6 poor metabolizers: start at 40 mg/day; if tolerated but response is inadequate, may increase after ≥4 weeks to 80 mg/day.

orthostatic hypotension off label: 10 mg twice daily initially; may increase to 18 mg twice daily based on response and tolerability.

hepatic impairment: Moderate (Child-Pugh B): use 50% of normal dose; severe (Child-Pugh C): use 25% of normal dose; mild (Child-Pugh A): no specific adjustment but consider cautious dosing.

renal impairment: No dose adjustment generally required, including ESRD, though exposure may be modestly increased.

older adults: Not well studied; use extreme caution, start at the low end of the dose range, and monitor cardiovascular status closely.

Simple Explanation

In children, doses are based on weight and increased slowly over days to weeks. In adults, treatment typically starts at 40 mg/day, increases to 80 mg/day after a few days, and can go up to 100 mg/day if needed. Patients with liver problems or certain genetic differences in metabolism (CYP2D6 poor metabolizers) take lower doses or increase more slowly.

Pregnancy, Breastfeeding, and Special Groups

Use in special populations requires individualized risk–benefit assessment and shared decision-making.

👶Pregnancy

Human data are limited but increasing; current evidence does not show a large increase in major birth defects, but subtle risks cannot be excluded. For pregnant patients with ADHD, nonpharmacologic therapies are preferred first-line when symptoms are mild to moderate. For moderate to severe ADHD, continuing or starting medication may be reasonable if the benefits (e.g., reduced accidents, better functioning) outweigh potential risks. Use the lowest effective dose and avoid polypharmacy. Pregnancy registries are available to track outcomes.

🤱Breastfeeding

It is not known whether atomoxetine is present in human breast milk. The decision to breastfeed while on atomoxetine should consider the benefits of breastfeeding, the mother’s need for treatment, and potential infant risks. If used, monitor infants for irritability, feeding problems, weight gain issues, and sleep disturbance.

👧Children & Adolescents (Under 18)

Approved for ADHD in children ≥6 years and adolescents. Atomoxetine may be preferred when stimulant diversion, misuse, or tic disorders are concerns. Monitor growth (height and weight), appetite, sleep, mood, blood pressure, heart rate, and emergent suicidal ideation or behavioral changes.

👴Older Adults (65+)

Use with caution; clinical experience is limited. Older adults may be more susceptible to cardiovascular adverse effects and drug interactions. Consider lower starting doses and more frequent monitoring.

🔬Liver Impairment

Moderate to severe hepatic impairment significantly increases exposure; doses should be reduced to 50% (moderate) or 25% (severe) of the usual dose and titrated carefully with close monitoring.

💧Kidney Impairment

No specific adjustment is typically needed, but comorbid cardiovascular disease and polypharmacy should be considered.

Clinical Monitoring

  • Suicidality and behavior: Monitor all patients—especially children and adolescents—for clinical worsening, suicidal thoughts or behavior, and unusual changes in behavior, particularly during the first few months and during dose changes. Caregivers should actively observe and report concerns.
  • Cardiovascular status: Obtain cardiovascular history and family history of sudden death or arrhythmia; perform physical exam prior to starting. Consider baseline ECG if history suggests cardiac disease. Monitor blood pressure and heart rate at baseline, after dose increases, and periodically.
  • Liver function: Check liver enzymes if symptoms suggest hepatic injury (e.g., jaundice, dark urine, abdominal pain, unexplained fatigue), and for several weeks after discontinuation if injury occurs.
  • Growth and weight: In children and adolescents, monitor weight, height, BMI, and appetite regularly (e.g., baseline, every 3–6 months).
  • Sleep and behavior: Track sleep patterns, irritability, aggression, psychosis, or manic symptoms; adjust treatment if problematic.
  • Urinary symptoms: Ask about urinary hesitancy or retention, particularly in patients with prior urinary problems.
  • ADHD symptom control and functioning: Use standardized scales where possible and assess school/work performance, organization, relationships, and quality of life.
  • Drug interactions and adherence: Periodically review all medications, including OTC and herbal products, and check for missed doses or incorrect use.

Available Formulations

  • Capsules, Oral (US): 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg (brand Strattera [discontinued] and multiple generics).
  • Capsules, Oral (Canada): 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg (multiple generic brands).

How It Works

Atomoxetine selectively inhibits the presynaptic norepinephrine transporter (NET), increasing norepinephrine (and indirectly some dopamine) in certain brain regions, particularly the prefrontal cortex. This enhances attention, impulse control, and executive functioning. Unlike stimulants, atomoxetine has little direct effect on dopamine in reward pathways and has minimal activity at other receptor sites, which contributes to its lack of abuse potential.

Place in Treatment Algorithm

Atomoxetine is considered a second-line or alternative first-line treatment for ADHD, after or alongside stimulants depending on patient-specific factors. It may be a particularly good choice when:

- There is a history (personal or family) of substance use disorder or concern about stimulant misuse/diversion.
- Stimulants cause unacceptable side effects (e.g., severe appetite suppression, insomnia, mood lability, tics).
- Comorbid tics or Tourette syndrome are present.
- A smoother, all-day effect is desired without peaks and troughs or without a controlled-substance designation.

Because onset is slower and effect size is somewhat smaller than stimulants, expectations should be managed and treatment integrated into a broader plan that includes behavioral therapy, school/work accommodations, and family support.

Frequently Asked Questions

What is atomoxetine used for?

Atomoxetine is a non-stimulant medicine used to treat attention-deficit/hyperactivity disorder (ADHD) in children 6 years and older, adolescents, and adults. It is often used when stimulants cause too many side effects, do not work well enough, or are not a good fit, such as in people with a history of substance misuse or tics. It is not approved to treat major depressive disorder (MDD).

How long does atomoxetine take to work?

Atomoxetine does not work immediately. Some people notice small improvements in focus or impulsivity after 1 to 2 weeks, but full benefit often takes 4 to 8 weeks. Because of this slower onset, it’s important not to stop too soon if early changes are modest.

How is atomoxetine different from stimulant medications?

Stimulants (like methylphenidate or amphetamine) typically work within 30–60 minutes and have stronger average effects but can cause appetite loss, insomnia, and have abuse potential. Atomoxetine has no known abuse potential and is not a controlled substance. It works by increasing norepinephrine, not directly stimulating dopamine reward pathways, and it builds up gradually over weeks instead of giving an immediate effect.

What is the suicide warning with atomoxetine?

Short-term studies in children and adolescents found a small increase in suicidal thoughts (0.4% on atomoxetine vs 0% on placebo). No suicides occurred in those trials. Because of this, all children and teens starting atomoxetine should be watched closely by family and clinicians for new or worsening depression, irritability, agitation, or suicidal thoughts, especially in the first few weeks or when the dose changes.

What are the most common side effects?

Common side effects include nausea, stomach pain, decreased appetite, dry mouth, headache, trouble sleeping, feeling tired, increased sweating, and mild increases in heart rate or blood pressure. Adults may also notice sexual side effects such as erectile or ejaculatory problems. Many side effects are worst in the first month and then improve.

Can atomoxetine cause serious heart or liver problems?

Serious heart events and severe liver injury are rare but have been reported. Atomoxetine can raise heart rate and blood pressure and has been linked to rare cases of sudden death, heart attack, or stroke in people with underlying heart disease. It has also caused rare cases of severe liver injury and liver failure. Before starting, your clinician will ask about heart history and family history, and you should report any chest pain, fainting, dark urine, yellow eyes/skin, or severe fatigue immediately.

Does atomoxetine affect growth in children?

Atomoxetine can slow weight gain and height growth in some children and teens, especially during the first 1–2 years. Over longer follow-up (2–5 years), many children show partial or full catch-up, but not all. Weight, height, and appetite should be monitored regularly, and the treatment plan may be adjusted if significant growth delay occurs.

How should I take atomoxetine?

You usually take atomoxetine once or twice a day, with or without food, at about the same time each day. Swallow the capsule whole—do not crush, chew, or open it. If the capsule breaks and powder gets in your eyes, rinse them with water and seek medical advice. Do not change your dose or timing without talking to your prescriber.

What if I miss a dose?

If you miss a dose, take it as soon as you remember, unless it’s close to the time for your next dose. If it is close, skip the missed dose and return to your normal schedule. Do not take two doses at once to make up for a missed dose.

Can I drink alcohol while taking atomoxetine?

Alcohol can increase some side effects of atomoxetine, like dizziness, drowsiness, and impaired judgment. It may also make it harder to recognize mood changes. It is safest to avoid or minimize alcohol use and discuss your alcohol intake with your prescriber.

Is atomoxetine safe during pregnancy or breastfeeding?

We don’t yet have enough high-quality data to say atomoxetine is completely safe in pregnancy or breastfeeding, but so far no major birth defect signal has emerged. For pregnant or breastfeeding patients with mild ADHD, non-medication approaches are preferred. For more severe ADHD, continuing or starting medicine may be reasonable if the benefits outweigh potential risks. This decision should be made with your prescriber as part of shared decision-making, and the lowest effective dose should be used.

Can atomoxetine be used with stimulants?

Sometimes atomoxetine is combined with a stimulant in patients who have only a partial response to either medicine alone, but this increases the complexity of treatment and the risk of side effects, especially cardiovascular ones. Combination therapy should only be done under close supervision by a clinician experienced with ADHD medications.

This medication information is for educational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Never take medication without a prescription from a licensed healthcare provider.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists